Expression and Clinical Relevance of SOX9 in Gastric Cancer
Table 1
Clinicopathological data and association with SOX9 in all patients included in the study.
All cases
SOX9 negative
SOX9 positive
%
%
%
Patients
333
100
58
17.4
275
82.6
Age
67.6±11.9
67.3±9.6
67.7±12.4
0.74
Range
32-95
46-83
32-95
Gender
Female
145
43.5
23
15.9
122
84.1
0.56
Male
188
56.5
35
18.6
153
81.4
Laurén classification
Intestinal
156
46.9
26
16.7
130
83.3
0.85
Diffuse
44
13.2
8
18.2
36
81.8
Mixed
87
26.1
17
19.5
70
80.5
Unclassified
46
13.8
Growth pattern
Expansive
61
18.3
13
21.3
48
78.7
0.34
Infiltrative
258
77.5
41
15.9
217
84.1
Unclassified
14
4.2
WHO classification
Tubular
146
43.8
25
17.1
121
82.9
0.99
Papillary
1
0.3
0
0.0
1
100.0
Poorly cohesive
37
11.1
7
18.9
30
81.1
Mucinous
7
2.1
1
14.3
6
85.7
Other variants
142
42.7
25
17.6
117
82.4
TNM
I
112
33.7
17
15.2
95
84.8
0.04
II
87
26.1
21
24.1
66
75.9
III
69
20.7
15
21.7
54
78.3
IV
65
19.5
5
7.7
60
92.3
Resection margins
R0
298
89.5
53
17.8
245
82.2
0.48
R1/R2
34
10.2
4
11.8
30
88.2
ND
1
0.3
Vascular invasion
No
140
42.0
23
16.4
117
83.6
0.66
Yes
190
57.1
35
18.4
155
81.6
ND
3
0.9
Perineural invasion
No
173
52.0
33
19.1
140
80.9
0.47
Yes
159
47.7
25
15.7
134
84.3
ND
1
0.3
β-Catenin nuclear expression
No
219
65.8
43
19.6
176
80.4
0.07
Yes
91
27.3
10
11.0
81
89.0
ND
23
6.9
Chemotherapy
Yes
124
37.2
27
46.6
97
35.8
0.14
No
205
61.6
31
53.4
174
64.2
ND
4
1.2
Notes. values (statistical significance ) were obtained using Student’s -test for the continuous variable, Fisher’s exact test (2-sided), and chi-square () test for categorical variables. Comparisons with . ND = not determined; SD = standard deviation.
